XTL Biopharmaceuticals Ltd.
XTLB · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 78.4% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -14.9% | 100% | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $0 | $0 |
| Sales & Mktg Exp. | -$0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $0 | $0 |
| Operating Income | -$1 | -$1 | -$0 | -$0 |
| % Margin | -281% | -471.6% | – | – |
| Other Income/Exp. Net | $0 | $0 | -$0 | $1 |
| Pre-Tax Income | -$0 | -$1 | -$1 | $0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$1 | $0 |
| % Margin | -88.2% | -341.4% | – | – |
| EPS | -0.04 | -0.1 | -0.13 | 0.09 |
| % Growth | 60% | 23.1% | -244.4% | – |
| EPS Diluted | -0.04 | -0.1 | -0.13 | 0.09 |
| Weighted Avg Shares Out | 7 | 5 | 5 | 5 |
| Weighted Avg Shares Out Dil | 7 | 5 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | -$0 | $0 |
| EBITDA | -$0 | -$0 | -$1 | $0 |
| % Margin | -148.5% | -96.3% | – | – |